If gastroparesis symptoms exist, a dose reduction in GLP-1 analog may be considered, with a focus on patient-specific factors, including risk for hyperglycemia and the potential for using pro-motility agents to ameliorate GLP-1 analog-related delayed GE [89]. Here, GLP1R is linked to Hyperglycemia.